Clinical Oncology Next Generation Sequencing Market Expected to Grow at a CAGR of 15.86% from 2023 to 2031

Companies covered in this report are Illumina Inc., Thermo Fisher Scientific, Agilent Technologies, F. Hoffmann-La Roche Ltd., Myriad Genetics, Perkin Elmer, Caris Life Sciences, Partek, Inc., Eurofins Scientific, and Qiagen N.V., Foundation Medicine, Pacific Bioscience, Oxford Nanopore Technologies Ltd., Paradigm Diagnostics, Beijing Genomics Institute (BGI), Takara Bio, Inc, Creative-Biolabs

Jersey City, NJ, Dec. 05, 2023 (GLOBE NEWSWIRE) -- InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global  Clinical Oncology Next Generation Sequencing Market - (By Application Type (Screening, Companion Diagnostics, and Other Diagnostics), By End User (Hospitals, Clinics, and Laboratories), By Technology Type (Whole Genome Sequencing, Whole Exome Sequencing, and Targeted Sequencing & Resequencing), By Workflow Type (NGS Pre-Sequencing, NGS Sequencing, and NGS Data Analysis)), Trends, Industry Competition Analysis, Revenue and Forecast To 2031."

According to the latest research by InsightAce Analytic, the Global Clinical Oncology Next Generation Sequencing Market is expected to raise with a CAGR of 15.86% during the forecast period of 2023-2031.

Next-generation sequencing is a DNA or RNA technology that allows several reactions to occur simultaneously. This is one of the most significant uses of next-generation sequencing in oncology. NGS has altered cancer genetics in recent years by giving researchers increased access to genomic and transcriptome data. Oncology screening for therapeutic applications employs next-generation tumour and germline DNA sequencing.

The global clinical oncology next-generation sequencing market is driven by factors including the increasing popularity of personalized medicine in clinical oncology, the decreasing cost of genetic medicine, the rising prevalence of cancer, the increasing need for early cancer diagnosis and treatment, and the ongoing advancements in cancer research. Innovative technologies such as next-generation sequencing are being deployed to alleviate this global burden and reduce mortality rates. As a result, the clinical oncology next-generation market is expanding more rapidly.

Free PDF Report Brochure @

Recent Developments:

  • In July 2023, Illumina Inc. and Pillar Biosciences Inc. have formed a strategic relationship to offer Pillar's range of oncology tests worldwide as part of Illumina's collection of oncology solutions. The agreement will lead to an unparalleled provision of supplementary next-generation sequencing solutions that will improve the efficiency, precision, and cost-effectiveness of oncology testing through advanced sequencing techniques, thereby enhancing patient access to personalized cancer treatment options.
  • In May 2023, Thermo Fisher Scientific and Pfizer joined forces to enhance the availability of advanced genetic testing for breast and lung cancer patients in more than 30 countries across Africa, the Middle East, Latin America, and Asia. These regions previously faced limitations or lack of access to state-of-the-art genomic testing.

Clinical Oncology Next Generation Sequencing Market Report Scope:

Report AttributeSpecifications
Growth Rate CAGRCAGR of 15.86 % from 2023 to 2031
Quantitative UnitsRepresentation of revenue in US$ Million and CAGR from 2023 to 2031
Historic Year2019 to 2022
Forecast Year2023-2031
Report CoverageThe forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends
Segments CoveredBy Application Type, By End User, By Technology Type, By Workflow Type
Regional ScopeNorth America; Europe; Asia Pacific; Latin America; Middle East & Africa
Country ScopeU.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South East Asia; South Korea

Need Specific Chapter from the Report @

List of Prominent Players in the Global Clinical Oncology Next-Generation Sequencing Market:

  • Illumina Inc.
  • Thermo Fisher Scientific
  • F. Hoffmann-La Roche Ltd.
  • Agilent Technologies
  • Myriad Genetics
  • Perkin Elmer
  • Caris Life Sciences
  • Partek, Inc.
  • Eurofins Scientific
  • Qiagen N.V. 
  • Foundation Medicine
  • Pacific Bioscience
  • Oxford Nanopore Technologies Ltd.
  • Paradigm Diagnostics
  • Beijing Genomics Institute (BGI)
  • Takara Bio, Inc
  • Creative-Biolabs
  • Others

Market Dynamics:


Personalized medicine and cancer advancements are expected to substantially impact the clinical oncology next-generation sequencing market. Rising cancer prevalence, high acceptability of sequencing-based diagnostics platforms among practising oncologists, lower genetic sequencing costs, and higher government R&D funding are some of the factors projected to drive market expansion. On the other hand, the widespread use of this technique over single-gene testing, as well as the increased use of clinical oncology next-generation sequencing technology and platforms in academic projects, will create a slew of new opportunities, pushing the clinical oncology next-generation sequencing market forward.


The high cost of technology is a major limitation on the growth of the clinical oncology next-generation sequencing market over the predicted period. High costs associated with sequencing platform installation, low outsourced service efficiency, and restricted availability of sequencing platforms in specific geographic markets are all projected to restrain the overall growth of the clinical oncology next-generation sequencing market. Moreover, the key constraining factors for the market evaluated are a lack of computational efficiency for data administration and an inadequate reimbursement policy.

Regional Trends:

The North American Global Clinical Oncology Next Generation Sequencing Market is expected to register a major market share in revenue and it is projected to grow at a high CAGR in the near future. The increasing frequency of chronic diseases is expected to boost the country's market. Cancer has a high incidence and fatality rate, which boosts the need for clinical oncology NGS platforms, enhancing the market under consideration. Furthermore, the region's high concentration of important players, growing Food and Drug Administration approvals, strategic alliances, and substantial expenditure in research & development activities are projected to enhance the market. In addition, Asia-Pacific is predicted to increase substantially during the projection period as pre-sequencing techniques in this region become more automated.

Curious about this latest version of the report? Enquiry Before Buying:

Segmentation of Global Clinical Oncology Next Generation Sequencing Market-

By Technology Type-

  • Whole Genome Sequencing
  • Whole Exome Sequencing
  • Targeted Sequencing & Re-sequencing

By End-User-

  • Hospitals
  • Clinics
  • Laboratories

By Application-

  • Screening
  • Companion Diagnostics
  • Other Diagnostics

By Workflow Type-

  • NGS Pre-Sequencing
  • NGS Sequencing
  • NGS Data Analysis

By Region-

North America-

  • The US
  • Canada
  • Mexico


  • Germany
  • The UK
  • France
  • Italy
  • Spain
  • Rest of Europe


  • China
  • Japan
  • India
  • South Korea
  • South East Asia
  • Rest of Asia Pacific

Latin America-

  • Brazil
  • Argentina
  • Rest of Latin America

 Middle East & Africa-

  • GCC Countries
  • South Africa
  • Rest of Middle East and Africa

Read Report Snapshot:

About Us:

InsighAce Analytic is a specializing in market research and consulting services that helps in building business strategies. Our mission is to provide high quality insights with using data analytics techniques and visualization tools that drives the disruption and innovation in market research industry. Our expertise is in providing syndicated and custom market intelligence reports with in-depth analysis and key market insights in a timely and cost-effective manner.

Follow Us @

Subscribe Our Exclusive Newsletters @


Contact Data